Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
The first and only sports competition for kids and teens living with bleeding disorders returns to Nevada next year. Here’s h…
We share a TV news report about a Maryland mother who advocated for her son and then learned she also had a primary immune de…
Bringing transformative, single-dose treatments to patients means working through new questions. CSL Behring’s Diego Sacrista…
We share a news report from California about a mother-daughter duo who share a diagnosis with primary immune deficiency.
We share a recent sponsored article in Politico and reports from Danish news outlets.
We share a report about a 24-year-old with hemophilia B who recently received gene therapy in California.
We share a report about a 32-year-old with hemophilia B who recently received gene therapy at Harvard-affiliated Brigham and …
Primary immune deficiency is a group of rare diseases that makes people vulnerable to frequent and hard-to-treat infections.
Get an update on CSL’s commitment to sustainability and where we are prioritizing action.
Americas
Asia Pacific
Middle East
Europe
